Tag: respiratory syncytial virus (RSV)

1. Prophylactic nirsevimab lowered the incidence of respiratory syncytial virus (RSV)-associated lower respiratory tract infection compared to the placebo group. 2. Nirsevimab had a favorable safety profile without causing hypersensitivity reactions. Evidence Rating Level: 1 (Excellent) Study Rundown: Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract disease...
1. The respiratory syncytial virus (RSV) fusion (F) vaccine given to pregnant women did not meet efficacy criteria against RSV-associated lower respiratory tract infection in infants compared to the placebo group, but did show evidence of secondary benefits. 2. The RSV F vaccine was shown to have a safety profile...
1. In this study of children admitted with acute respiratory illness, about one-third were respiratory syncytial virus (RSV)-positive and higher rates of hospitalization were noted among younger children. 2. Among hospitalized, RSV-positive patients, age outside of 12 – 23 months, comorbid conditions, and premature birth was associated with higher likelihood...